VIVUS, Inc. (NASDAQ:VVUS)

biotech

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm. The biotech sector has been a wealth-creation engine in recent years. What is interesting here ...
Read Full Story »
down market

The 52-Week Low Club for Wednesday

August 13, 2014: Stocks making new 52-week lows today included the following four firms. Cree Inc. (NASDAQ: CREE) saw shares fall more than 10% to a new 52-week low of ...
Read Full Story »
153576724

Orexigen Irony: No VIVUS Bounce

VIVUS Inc. (NASDAQ: VVUS) investors have a lot to be disappointed about these days. America's ballooning waistline is reaching a critical level, yet VIVUS did not even manage to close ...
Read Full Story »
153576724

VIVUS Blows Out Estimates, but Qsymia Units Drop Sequentially

VIVUS Inc. (NASDAQ: VVUS) is going to have to explain how its diet pill Qsymia had lower prescription volumes sequentially. If you just look at the revenue number, it looks ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Apple, Intel, Chevron, Exxon, Qualcomm, Citigroup and More

Stocks are hitting new highs ahead of Friday's payrolls report, and investors are looking for upside while wanting to not get caught in the next sell-off. 24/7 Wall St. reviews ...
Read Full Story »
153576724

VIVUS Chances of a Stock Double Shrinking

VIVUS Inc. (NASDAQ: VVUS) is suffering from what looked like good news on the surface. The reality, and the catch about investing, is that things can often be much more ...
Read Full Story »
Netflix logo

More Analyst Sell Ratings as Markets Hit New Highs

Like any other item in the world, when a stock gets too expensive you just don't want to buy it. The higher the market pushes, the more we see high-profile ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Tesla, Verizon, VIVUS and More

Stocks are hitting new highs again as earnings season winds down, and now investors have to make careful considerations about how to position their portfolios. No one wants to knowingly ...
Read Full Story »
research

Four Biotech Stocks Called to Double

The biotech market has been on fire this year, and there is every indication that things will continue. With huge binary events right around the corner, and many of the ...
Read Full Story »
180519466

Nine Stocks That Could Double in 2014

Please note that this article has been updated to account for deletions and updates on the list of stocks that could double. The bull market run in 2013 was so ...
Read Full Story »
biotech

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Anybody that has been long the biotechnology sector for the past four years has had outstanding returns. Following four straight years of outperformance against the S&P 500, investor interest in ...
Read Full Story »
2014 in the box

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

All of the major firms on Wall Street we cover have prognostications and stock picks for 2014. The Cowen biotechnology team has a list of top 10 surprises that are ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AMR, Endo Health, T-Mobile, VIVUS and More

This week marks the last one of major earnings reports, and both the DJIA and S&P 500 Index have recently challenged new all-time highs. Investors and traders have to wonder which ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: BlackBerry, Micron, SanDisk, VIVUS and More

With the government shut down and with the debt ceiling debate breathing down everyone's neck, investors have to be wondering what they should buy, sell and hold (or even avoid). ...
Read Full Story »
Bull and Bear

Top Analyst Downgrades and Stocks to Sell: Cree, Melco, Monster, VIVUS and More

Investors frequently get to see the analyst upgrades and Buy ratings from Wall Street firms. What investors often do not get to see is when analyst downgrade stocks to sell ...
Read Full Story »